Bucillamine Prevents Afatinib-Mediated Inhibition of Epidermal Growth Factor Receptor Signaling

Bucillamine Prevents Afatinib-Mediated Inhibition of Epidermal Growth Factor Receptor Signaling

Molecular targeting therapies often cause characteristic adverse effects, such as skin rash during anti-epidermal growth factor receptor (EGFR) therapies, making treatment continuation difficult. In contrast, skin symptoms induced by EGFR inhibition are strongly correlated with the overall survival...

Full description

Bibliographic Details
Main Authors: Naoyuki Nishiya, Moeka Murai, Ayumi Hosoda, Honami Yonezawa, Norikazu Omori
Format: Article
Language:English
Published: MDPI AG 2019-11-01
Series:Pharmaceuticals
Subjects:
adverse effect
egfr-tki
skin rash
Online Access:https://www.mdpi.com/1424-8247/12/4/165

Similar Items

Similar Items